Resources

This table, produced by Public Health England to accompany 'Hepatitis C in England: 2017 report', collates the key statistics and information related to hepatitis C in England, including burden of infection; mortality and morbidity; incidence of infections; adequacy of harm reduction services; diagnosis rates, and the numbers of people accessing treatment.

On Friday 10th February 2017, HCV Action and NHS England held a Midlands & East Hepatitis C Educational Event in Nottingham. With hepatitis C Operational Delivery Networks (ODNs) still relatively new in operation, the event was held with the aim of offering the chance for ODNs across the Midlands and East region to come together to discuss their experiences, share best practice and develop solutions to some of the challenges they face as they seek to ensure the highest standards of hepatitis C care and treatment.

This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines.

These Scottish guidelines, updated in January 2016, provide expert guidance to Health Boards, Area Drug and Therapeutics Committees, and treating clinicians on the efficacy of available treatments for hepatitis C. They also act as a clinical reference source for NHS National Procurement to produce rankings on cost-effectiveness. Development of the guidance was a collaboration between Scotland's viral hepatitis clinical leads and MCN co-ordinators network, National Services Scotland, and Healthcare Improvement Scotland.